ReviewCancers2022
Estrogens, Cancer and Immunity.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 50 citations in OpenAlex.
- Sex-based immune differences influence tumor progression in head and neck squamous cell carcinoma.Oral oncology · 2026Article
- Intersecting Roles of Estrogens and Neutrophils in Modulating Innate Immunity in Cancer.Biomolecules · 2026Review
- Carcinogenic Medications: A Review of Specific Agents and Molecular Mechanisms of Carcinogenesis.Cancer reports (Hoboken, N.J.) · 2026Review
- R-loop editing by DNA cytosine deaminase APOBEC3B modulates the activity of oestrogen receptor enhancers.Nature communications · 2026Article
- Estrogen-Induced Hypermethylation Silencing ofCells · 2026Article
- The dysregulation of the immune microenvironment during endometrial intraepithelial neoplasia serves as a marker of endometrial carcinogenesis.Frontiers in immunology · 2026Review
- Sex differences in innate immune cell responses: Impact on cancer immunity and response to therapy.Frontiers in immunology · 2026Review
- Sex-based survival disparities in patients with stage I-III non-small cell lung cancer vary by treatment modality.Frontiers in oncology · 2026Article
- Estrogen-Driven Breast Carcinogenesis in a Rat Model is Linked to Retroelement Activation and Inflammation and is Susceptible to Lamivudine Treatment.Breast cancer (Dove Medical Press) · 2026Article
- Novel and simplified model for the precise identification of concurrent bacterial infections in patients aged 60 years and older with acute-on-chronic liver diseases: a nationwide, multicentre, prospective cohort study.Hepatology international · 2025Article
- Multi-omics protein signaling networks identify sex-specific therapeutic candidates in lung adenocarcinoma.Biology of sex differences · 2025Article
- Steroid hormones as modulators of anti-tumoural immunity.Nature reviews. Endocrinology · 2025Review
- Article
- Impact of relative estradiol changes during ovarian stimulation on blastocyst formation and live birth in assisted reproductive technology.Scientific reports · 2025Article
- Ultrasound-Assisted Microcontinuous Process Facilitates the Selective Deuteration of Steroid Hormones.Journal of labelled compounds & radiopharmaceuticals · 2025Article
- Personalized Lifestyle Interventions for Prevention and Treatment of Obesity-Related Cancers: A Call to Action.Cancers · 2025Article
- Identifying Sex Differences in Lung Adenocarcinoma Using Multi-Omics Integrative Protein Signaling Networks.bioRxiv : the preprint server for biology · 2025Article
- A Pan-Cancer Analysis of Age and Sex Differences in Cancer Incidence and Survival in the United States, 2001-2020.Cancers · 2025Article
- Mechanistic insights and biomarker discovery in immune cell aging and age-associated diseases.Frontiers in immunology · 2025Review
- Role of Nanoformulations in the Treatment of Lung Cancer.Recent patents on nanotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sex hormones are included in many physiological and pathological pathways. Estrogens belong to steroid hormones active in female sex. Estradiol (E2) is the strongest female sex hormone and, with its receptors, contributes to oncogenesis, cancer progression and response to treatment. In recent years, a role of immunosurveillance and suppression of immune response in malignancy has been well defined, forming the basis for cancer immunotherapy. The interplay of sex hormones with cancer immunity, as well as the response to immune checkpoint inhibitors, is of interest. In this review, we investigate the impact of sex hormones on natural immune response with respect to main active elements in anticancer immune surveillance: dendritic cells, macrophages, lymphocytes and checkpoint molecules. We describe the main sex-dependent tumors and the contribution of estrogen in their progression, response to treatment and especially modulation of anticancer immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.